2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF

Cancer Cell

Volumn 3, Issue 4, 2003, Pages 363-375

  Mabjeesh, Nicola J ^a,c   Escuin, Daniel ^a   LaVallee, Theresa M ^b   Pribluda, Victor S ^b   Swartz, Glenn M ^b   Johnson, Michelle S ^b   Willard, Margaret T ^a   Zhong, Hua ^a   Simons, Jonathan W ^a   Giannakakou, Paraskevi ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ENTREMED INC   (United States)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TUBULIN; VASCULOTROPIN; 2-METHOXYESTRADIOL; DNA BINDING PROTEIN; DRUG DERIVATIVE; ENDOTHELIAL CELL GROWTH FACTOR; ESTRADIOL; HIF1A PROTEIN, HUMAN; HIF1A PROTEIN, MOUSE; HYPOXIA INDUCIBLE FACTOR 1; LYMPHOKINE; MESSENGER RNA; NUCLEAR PROTEIN; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DOWNSTREAM PROCESSING; DRUG MECHANISM; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MICROTUBULE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; TRANSCRIPTION INITIATION; ANIMAL; BREAST TUMOR; CELL CULTURE; CONFOCAL MICROSCOPY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NORTHERN BLOTTING; PATHOLOGY; VASCULARIZATION;

ANIMALIA;

ANIMALS; BLOTTING, NORTHERN; BREAST NEOPLASMS; DNA-BINDING PROTEINS; ENDOTHELIAL GROWTH FACTORS; ESTRADIOL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MICE; MICROSCOPY, CONFOCAL; MICROTUBULES; MODELS, ANIMAL; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 10744231706     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00077-1     Document Type: Article

References (72)

1. Aebersold D.M., Burri P., Beer K.T., Laissue J., Djonov V., Greiner R.H., Semenza G.L. Expression of hypoxia-inducible factor-1alpha. a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer Cancer Res. 61:2001;2911-2916.
2. Aizu-Yokota E., Susaki A., Sato Y. Natural estrogens induce modulation of microtubules in Chinese hamster V79 cells in culture. Cancer Res. 55:1995;1863-1868.
3. Attalla H., Makela T.P., Adlercreutz H., Andersson L.C. 2-Methoxyestradiol arrests cells in mitosis without depolymerizing tubulin. Biochem. Biophys. Res. Commun. 228:1996;467-473.
4. Banerjeei S.K., Zoubine M.N., Sarkar D.K., Weston A.P., Shah J.H., Campbell D.R. 2-Methoxyestradiol blocks estrogen-induced rat pituitary tumor growth and tumor angiogenesis. possible role of vascular endothelial growth factor Anticancer Res. 20:2000;2641-2645.
5. Beasley N.J., Leek R., Alam M., Turley H., Cox G.J., Gatter K., Millard P., Fuggle S., Harris A.L. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer. relationship to tumor biology and treatment outcome in surgically resected patients Cancer Res. 62:2002;2493-2497.
6. Belotti D., Vergani V., Drudis T., Borsotti P., Pitelli M.R., Viale G., Giavazzi R., Taraboletti G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2:1996;1843-1849.
7. Birner P., Schindl M., Obermair A., Plank C., Breitenecker G., Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 60:2000;4693-4696.
8. Birner P., Schindl M., Obermair A., Breitenecker G., Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors. its impact on prognosis and on response to chemotherapy Clin. Cancer Res. 7:2001;1661-1668.
9. Blakey D.C., Westwood F.R., Walker M., Hughes G.D., Davis P.D., Ashton S.E., Ryan A.J. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin. Cancer Res. 8:2002;1974-1983.
10. Blancher C., Moore J.W., Talks K.L., Houlbrook S., Harris A.L. Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res. 60:2000;7106-7113.
11. Bos R., Zhong H., Hanrahan C.F., Mommers E.C., Semenza G.L., Pinedo H.M., Abeloff M.D., Simons J.W., van Diest P.J., van der Wall E. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J. Natl. Cancer Inst. 93:2001;309-314.
12. Brahimi-Horn C., Berra E., Pouyssegur J. Hypoxia. the tumor's gateway to progression along the angiogenic pathway Trends Cell Biol. 11:2001;S32-S36.
13. Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 294:2001;1337-1340.
14. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P.et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394:1998;485-490.
15. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C.et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 380:1996;435-439.
16. Chauhan D., Catley L., Hideshima T., Li G., Leblanc R., Gupta D., Sattler M., Richardson P., Schlossman R.L., Podar K.et al. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood. 100:2002;2187-2194.
17. Cushman M., He H.M., Katzenellenbogen J.A., Lin C.M., Hamel E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J. Med. Chem. 38:1995;2041-2049.
18. Cushman M., He H.M., Katzenellenbogen J.A., Varma R.K., Hamel E., Lin C.M., Ram S., Sachdeva Y.P. Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerization and cancer cell growth. J. Med. Chem. 40:1997;2323-2334.
19. D'Amato R.J., Lin C.M., Flynn E., Folkman J., Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc. Natl. Acad. Sci. USA. 91:1994;3964-3968.
20. Dark G.G., Hill S.A., Prise V.E., Tozer G.M., Pettit G.R., Chaplin D.J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57:1997;1829-1834.
21. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A.et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 107:2001;43-54.
22. Folkman J. Angiogenesis-dependent diseases. Semin. Oncol. 28:2001;536-542.
23. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16:1996;4604-4613.
24. Fotsis T., Zhang Y., Pepper M.S., Adlercreutz H., Montesano R., Nawroth P.P., Schweigerer L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature. 368:1994;237-239.
25. Gagescu R. Another star on drugs. Nat. Rev. Mol. Cell Biol. 1:2000;5.
26. Giannakakou P., Sackett D.L., Kang Y.K., Zhan Z., Buters J.T., Fojo T., Poruchynsky M.S. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 272:1997;17118-17125.
27. Giatromanolaki A., Koukourakis M.I., Sivridis E., Turley H., Talks K., Pezzella F., Gatter K.C., Harris A.L. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/ molecular profile of tumours and survival. Br. J. Cancer. 85:2001;881-890.
28. Goldberg M.A., Schneider T.J. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J. Biol. Chem. 269:1994;4355-4359.
29. Grosios K., Holwell S.E., McGown A.T., Pettit G.R., Bibby M.C. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer. 81:1999;1318-1327.
30. Hale I.L., Matsumoto B. Resolution of subcellular detail in thick tissue sections. immunohistochemical preparation and fluorescence confocal microscopy Methods Cell Biol. 38:1993;289-324.
31. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer. 2:2002;38-47.
32. Hergovich A., Lisztwan J., Barry R., Ballschmieter P., Krek W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat. Cell Biol. 5:2003;64-70.
33. Hlatky L., Hahnfeldt P., Folkman J. Clinical application of antiangiogenic therapy. microvessel density, what it does and doesn't tell us J. Natl. Cancer Inst. 94:2002;883-893.
34. Hopfl G., Wenger R.H., Ziegler U., Stallmach T., Gardelle O., Achermann R., Wergin M., Kaser-Hotz B., Saunders H.M., Williams K.J.et al. Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor. Cancer Res. 62:2002;2962-2970.
35. Huang C.Y., Fujimura M., Noshita N., Chang Y.Y., Chan P.H. SOD1 down-regulates NF-kappaB and c-Myc expression in mice after transient focal cerebral ischemia. J. Cereb. Blood Flow Metab. 21:2001;163-173.
36. Isaacs J.S., Jung Y.J., Mimnaugh E.G., Martinez A., Cuttitta F., Neckers L.M. Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1alpha-degradative Pathway. J. Biol. Chem. 277:2002;29936-29944.
37. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J.M., Lane W.S., Kaelin W.G. Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation. implications for O2 sensing Science. 292:2001;464-468.
38. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., Kriegsheim A., Hebestreit H.F., Mukherji M., Schofield C.J.et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 292:2001;468-472.
39. Jeong J.W., Bae M.K., Ahn M.Y., Kim S.H., Sohn T.K., Bae M.H., Yoo M.A., Song E.J., Lee K.J., Kim K.W. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell. 111:2002;709-720.
40. Jiang B.H., Semenza G.L., Bauer C., Marti H.H. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am. J. Physiol. 271:1996;C1172-C1180.
41. Kachadourian R., Liochev S.I., Cabelli D.E., Patel M.N., Fridovich I., Day B.J. 2-methoxyestradiol does not inhibit superoxide dismutase. Arch. Biochem. Biophys. 392:2001;349-353.
42. Klauber N., Parangi S., Flynn E., Hamel E., D'Amato R.J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 57:1997;81-86.
43. Koukourakis M.I., Giatromanolaki A., Sivridis E., Simopoulos C., Turley H., Talks K., Gatter K.C., Harris A.L. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 53:2002;1192-1202.
44. Lakhani N.J., Sarkar M.A., Venitz J., Figg W.D. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy. 23:2003;165-172.
45. LaVallee T.M., Zhan X.H., Herbstritt C.J., Kough E.C., Green S.J., Pribluda V.S. 2-methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res. 62:2002;3691-3697.
46. Mabjeesh N.J., Post D.E., Willard M.T., Kaur B., Van Meir E.G., Simons J.W., Zhong H. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res. 62:2002;2478-2482.
47. Mack F.A., Rathmell W.K., Arsham A.M., Gnarra J., Keith B., Simon M.C. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell. 3:2003;75-88.
48. Masson N., Willam C., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 20:2001;5197-5206.
49. Maxwell P.H., Ratcliffe P.J. Oxygen sensors and angiogenesis. Semin. Cell Dev. Biol. 13:2002;29-37.
50. Maxwell P.H., Dachs G.U., Gleadle J.M., Nicholls L.G., Harris A.L., Stratford I.J., Hankinson O., Pugh C.W., Ratcliffe P.J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA. 94:1997;8104-8109.
51. Mayer T.U., Kapoor T.M., Haggarty S.J., King R.W., Schreiber S.L., Mitchison T.J. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 286:1999;971-974.
52. Minchenko A., Bauer T., Salceda S., Caro J. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab. Invest. 71:1994;374-379.
53. Post D.E., Van Meir E.G. Generation of bidirectional hypoxia/HIF- responsive expression vectors to target gene expression to hypoxic cells. Gene Ther. 8:2001;1801-1807.
54. Pribluda V.S., Gubish E.R. Jr., Lavallee T.M., Treston A., Swartz G.M., Green S.J. 2-Methoxyestradiol. an endogenous antiangiogenic and antiproliferative drug candidate Cancer Metastasis Rev. 19:2000;173-179.
55. Purohit A., Singh A., Ghilchik M.W., Reed M.J. Inhibition of tumor necrosis factor alpha-stimulated aromatase activity by microtubule-stabilizing agents, paclitaxel and 2-methoxyestradiol. Biochem. Biophys. Res. Commun. 261:1999;214-217.
56. Ratcliffe P.J. New insights into an enigmatic tumour suppressor. Nat. Cell Biol. 5:2003;7-8.
57. Risau W. Mechanisms of angiogenesis. Nature. 386:1997;671-674.
58. Ryan H.E., Lo J., Johnson R.S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17:1998;3005-3015.
59. Ryan H.E., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J.M., Johnson R.S. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 60:2000;4010-4015.
60. Schindl M., Schoppmann S.F., Samonigg H., Hausmaninger H., Kwasny W., Gnant M., Jakesz R., Kubista E., Birner P., Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin. Cancer Res. 8:2002;1831-1837.
61. Seegers J.C., Lottering M.L., Grobler C.J., van Papendorp D.H., Habbersett R.C., Shou Y., Lehnert B.E. The mammalian metabolite, 2-methoxyestradiol, affects P53 levels and apoptosis induction in transformed cells but not in normal cells. J. Steroid Biochem. Mol. Biol. 62:1997;253-267.
62. Semenza G.L. HIF-1. mediator of physiological and pathophysiological responses to hypoxia J. Appl. Physiol. 88:2000;1474-1480.
63. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol. 64:2002;993-998.
64. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:1992;843-845.
65. Sweeney C.J., Miller K.D., Sissons S.E., Nozaki S., Heilman D.K., Shen J., Sledge G.W. Jr. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 61:2001;3369-3372.
66. Talks K.L., Turley H., Gatter K.C., Maxwell P.H., Pugh C.W., Ratcliffe P.J., Harris A.L. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157:2000;411-421.
67. Taraboletti G., Micheletti G., Rieppi M., Poli M., Turatto M., Rossi C., Borsotti P., Roccabianca P., Scanziani E., Nicoletti M.I.et al. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin. Cancer Res. 8:2002;1182-1188.
68. Tozer G.M., Prise V.E., Wilson J., Cemazar M., Shan S., Dewhirst M.W., Barber P.R., Vojnovic B., Chaplin D.J. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate. intravital microscopy and measurement of vascular permeability Cancer Res. 61:2001;6413-6422.
69. Wang G.L., Jiang B.H., Rue E.A., Semenza G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA. 92:1995;5510-5514.
70. Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 324:1991;1-8.
71. Wenger R.H. Mammalian oxygen sensing, signalling and gene regulation. J. Exp. Biol. 203:2000;1253-1263.
72. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., Simons J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:1999;5830-5835.